Duke University

Dana-farber-cancer Institute Inc.

Christopher B Newgard

Bruce M Spiegelman

Geoffrey S Ginsburg

Jiandie Lin

William E Kraus

Elizabeth R Hauser

L Kristin Newby

Svati Shah

Jonathan C Schisler

Samuel B Stephens

Methods of assessing the risk of cardiovascular disease in a subject by detecting the level of at least one metabolite in a sample from the subject are disclosed herein. The level of the metabolite is indicative of the risk of cardiovascular disease in the subject. The metabolites may be acylcarnitines, amino acids, ketones, free fatty acids or hydroxybutyrate. The cardiovascular disease may be risk of a cardiovascular event, presence of coronary artery disease or risk of development of coronary artery disease.

Predicting coronary artery disease and risk of cardiovascular events

The present invention provides methods for treating lipid-related diseases and disorders, e.g., hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, cardiovascular disease, obesity, and type II diabetes, and for modulating lipid biosynthesis, lipid transport, plasma triglyceride levels and/or plasma cholesterol levels, by modulating the expression or activity of PGC-1&#x3b2;. Methods for identifying compounds which are capable of treating or preventing a lipid-related disease or disorder are also described.

Compositions and methods for modulating PGC-1&#x3b2; to treat lipid-related diseases and disorders

Methods of modulating blood glucose levels treating hyperglycemia and related complications and conditions by administration of a VGF biomolecule to a patient in need of such treatment are provided. Methods of enhancing insulin secretion from islet beta cells in a mammal exhibiting reduced insulin secretion by administration of a therapeutically effective amount of a VGF biomolecule are also provided.

Peptide therapy for hyperglycemia

Growing community of inventors

Durham, NC, United States of America

Christopher B Newgard